secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001193125-25-250656
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora reports NMRA-215 preclinical data: up to 19% monotherapy weight loss, 26% with semaglutide
--------------------------------------------------------------------------------

- NMRA-215 showed class-leading 19% weight loss as monotherapy with semaglutide-like induction in DIO mice.
- Combination with high-dose semaglutide achieved up to 26% weight loss, best-in-class vs. NLRP3 inhibitors.
- Preclinical data support potential as oral, brain-penetrant NLRP3 inhibitor for obesity.
- Neumora plans to initiate Phase 1 clinical study for NMRA-215 in Q1 2026.
- Additional data to be presented at virtual R&D day on October 27, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525250656/0001193125-25-250656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525250656/nmra-20251027.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer